- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
München, Techn. Univ., Diss., 2009
- Keyword
-
Molekülstruktur
Strukturbiologie
Zwischenmolekulare Kraft
Supramolekulare Chemie
- Creator
- URN
-
urn:nbn:de:bvb:91-diss-20091112-886031-1-8
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Object type
- Hochschulschrift
Associated
Other Objects (12)
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Evolution of the p53-MDM2 pathway
Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis
Small-Molecule Inhibitors of p53-MDM2 interactions
Serumantikörper gegen die Proteine p53, mdm2 und p21-waf1 und Nachweis der Proteine p53 und mdm2 in menschlichen Tumorgeweben
Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53
Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
NAT 10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2
Engineering a synthetic p53-Mdm2 network in budding yeast
Explaining oscillations and variability in the p53-Mdm2 system
Mad1 destabilizes p53 by preventing PML from sequestering MDM2
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Evolution of the p53-MDM2 pathway
Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis
Small-Molecule Inhibitors of p53-MDM2 interactions
Serumantikörper gegen die Proteine p53, mdm2 und p21-waf1 und Nachweis der Proteine p53 und mdm2 in menschlichen Tumorgeweben
Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53
Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
NAT 10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2
Engineering a synthetic p53-Mdm2 network in budding yeast
Explaining oscillations and variability in the p53-Mdm2 system
Mad1 destabilizes p53 by preventing PML from sequestering MDM2
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Evolution of the p53-MDM2 pathway
Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis
Small-Molecule Inhibitors of p53-MDM2 interactions
Serumantikörper gegen die Proteine p53, mdm2 und p21-waf1 und Nachweis der Proteine p53 und mdm2 in menschlichen Tumorgeweben
Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53
Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
NAT 10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2
Engineering a synthetic p53-Mdm2 network in budding yeast
Explaining oscillations and variability in the p53-Mdm2 system